新検索ページはこちら
ログイン
お問い合わせ
有効性評価に基づく前立腺がん検診ガイドライン
書誌情報
引用文献
添付書類1
添付書類1：採用文献リスト 英文69+和文3＝72文献
| 分類 | ガイドライン引用No | Auther | Title | Journal | Volumes | Issue | Pages | Year |
| DRE | 23 | Gilliland F, Becker TM, Smith A, Key CR, Samet JM. | Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. | Cancer Epidemiol Biomarkers Prev | 3 | 2 | 105-11 | 1994 |
| DRE | 24 | Friedman GD, Hiatt RA, Quesenberry CP Jr, Selby JV. | Case-control study of screening for prostatic cancer by digital rectal examinations. | Lancet | 337 | 1526-9 | 1991 | |
| DRE | 25 | Richert-Boe KE, Humphrey LL, Glass AG, Weiss NS. | Screening digital rectal examination and prostate cancer mortality: a case-control study. | J Med Screen | 5 | 2 | 99-103 | 1998 |
| DRE | 26 | Weinmann S, Richert-Boe K, Glass AG, Weiss NS. | Prostate cancer screening and mortality: a case-control study (United States). | Cancer Causes Control | 15 | 2 | 133-8 | 2004 |
| DRE | 27 | Jacobsen SJ, Bergstralh EJ, Katusic SK, Guess HA, Darby CH, Silverstein MD, Oesterling JE, Lieber MM. | Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. | Urology | 52 | 2 | 173-9 | 1998 |
| DRE/PSA | 28 | Mistry K, Cable G. | Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. | J Am Board Fam Pract | 16 | 2 | 95-101 | 2003 |
| PSA | 30 | Labrie F, Candas B, Cusan L, Gomez JL, Belanger A, Brousseau G, Chevrette E, Levesque J. | Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. | Prostate | 59 | 3 | 311-8 | 2004 |
| PSA | 31 | Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, Diamond P, Lévesque J, Belanger A. | Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. | Prostate | 38 | 2 | 83-91 | 1999 |
| PSA | 32 | Sandblom G, Varenhorst E, Löfman O, Rosell J, Carlsson P. | Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. | Eur Urol | 46 | 717-24 | 2004 | |
| PSA | 33 | Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. | Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. | Eur Urol | 51 | 3 | 659-64 | 2004 |
| PSA | 34 | Ilic D, O'Connor D, Green S, Wilt T. | Screening for prostate cancer: a Cochrane systematic review. | Cancer Causes Control | 18 | 3 | 279-85 | 2007 |
| PSA | 35 | Ciatto S, Gervasi G, Gorini G, Lombardi C, Zappa M, Crocetti E. | Prostate cancer specific mortality in the Florence screening pilot study cohort 1992-1993. | Eur J Cancer | 42 | 12 | 1858-62 | 2006 |
| PSA | 36 | 中川修一，中村晃和，渡辺泱． | 前立腺がん検診の有効性と適切な受診間隔を検討するためのケース・コントロール研究. | 日本泌尿器科学会雑誌 | 89 | 11 | 894-8 | 1998 |
| PSA | 37 | Concato J, Wells CK, Horwitz RI, Penson D, Fincke G, Berlowitz DR, Froehlich G, Blake D, Vickers MA, Gehr GA, Raheb NH, Sullivan G, Peduzzi P. | The effectiveness of screening for prostate cancer: a nested case-control study. | Arch Intern Med | 166 | 38-43 | 2006 | |
| PSA | 38 | Kopec JA, Goel V, Bunting PS, Neuman J, Sayre EC, Warde P, Levers P, Fleshner N. | Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. | J Urol | 174 | 495-9 | 2005 | |
| PSA | 39 | Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. | Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. | BMJ | 325 | 7367 | 740 | 2002 |
| PSA | 40 | Perron L, Moore L, Bairati I, Bernard PM, Meyer F. | PSA screening and prostate cancer mortality. | CMAJ | 166 | 5 | 586-91 | 2002 |
| PSA | 41 | Coldman AJ, Phillips N, Pickles TA. | Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. | CMAJ | 168 | 1 | 31-5 | 2003 |
| PSA | 42 | La Rosa F, Stracci F, Minelli L, Mastrandrea V. | Epidemiology of prostate cancer in the Umbria region of Italy: evidence of opportunistic screening effects. | Urology | 62 | 6 | 1040-4 | 2003 |
| PSA | 43 | Threlfall TJ, English DR, Rouse IL. | Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996. | Med J Aust | 169 | 21-4 | 1998 | |
| PSA | 44 | Skarsgard D, Tonita J. | Prostate cancer in Saskatchewan Canada, before and during the PSA era. | Cancer Causes Control | 11 | 79-88 | 2000 | |
| PSA | 45 | Majeed A, Babb P, Jones J, Quinn M. | Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998. | BJU Int | 85 | 1058-62 | 2000 | |
| PSA | 46 | Post PN, Kil PJ, Crommelin MA, Schapers RF, Coebergh JW. | Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in southeastern Netherlands, 1971-1995. | Eur J Cancer | 34 | 5 | 705-9 | 1998 |
| PSA | 47 | Brewster DH, Fraser LA, Harris V, Black RJ. | Rising incidence of prostate cancer in Scotland: increased risk or increased detection? | BJU Int | 85 | 463-73 | 2000 | |
| PSA | 48 | Roberts RO, Bergstralh EJ, Katusic SK, Lieber MM, Jacobsen SJ. | Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. | J Urol | 161 | 529-33 | 1999 | |
| PSA | 49 | Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, Penson DF, Weiss NS, Feuer EJ. | An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. | Am J Epidemiol | 160 | 11 | 1059-69 | 2004 |
| PSA | 50 | Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ. | Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. | Cancer Epidemiol Biomarkers Prev | 14 | 3 | 590-5 | 2005 |
| PSA | 51 | Baade PD, Coory MD, Aitken JF. | International trends in prostate-cancer mortality: the decrease is continuing and spreading. | Cancer Causes Control | 15 | 237-41 | 2004 | |
| PSA | 52 | Oberaigner W, Horninger W, Klocker H, Schönitzer D, Stühlinger W, Bartsch G. | Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. | Am J Epidemiol | 164 | 4 | 376-84 | 2006 |
| PSA | 53 | Vutuc C, Schernhammer ES, Haidinger G, Waldhör T. | Prostate cancer and prostate-specific antigen (PSA) screening in Austria. | Wien Klin Wochenschr | 117 | 13-14 | 457-61 | 2005 |
| PSA | 54 | Melia J, Dearnaley D, Moss S, Johns L, Coulson P, Moynihan C, Sweetman J, Parkinson MC, Eeles R, Watson M. | The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk. | Br J Cancer | 94 | 4 | 499-506 | 2006 |
| PSA | 55 | Catalona WJ, Antenor JA, Roehl KA, Moul JW. | Screening for prostate cancer in high risk populations. | J Urol | 168 | 5 | 1980-4 | 2002 |
| PSA | 56 | Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, Emond J. | Serum prostate specific antigen as pre-screening test for prostate cancer. | J Urol | 147 | 3 Pt 2 | 846-52 | 1992 |
| PSA | 57 | Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. | Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. | Lancet | 344 | 8937 | 1594-8 | 1994 |
| PSA | 58 | Imai K, Ichinose Y, Kubota Y, Yamanaka H, Sato J. | Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. | J Urol | 154 | 3 | 1085-9 | 1995 |
| PSA | 59 | Jacobsen SJ, Bergstralh EJ, Guess HA, Katusic SK, Klee GG, Oesterling JE, Lieber MM. | Predictive properties of serum-prostate-specific antigen testing in a community-based setting. | Arch Intern Med | 156 | 21 | 2462-8 | 1996 |
| PSA | 60 | Ito K, Yamamoto T, Kubota Y, Suzuki K, Fukabori Y, Kurokawa K, Yamanaka H. | Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. | Urology | 56 | 2 | 278-82 | 2000 |
| PSA | 61 | Hakama M, Stenman UH, Aromaa A, Leinonen J, Hakulinen T, Knekt P. | Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. | J Urol | 166 | 6 | 2189-92 | 2001 |
| PSA | 62 | van der Cruijsen-Koeter IW, van der Kwast TH, Schröder FH. | Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. | J Natl Cancer Inst | 95 | 19 | 1462-6 | 2003 |
| PSA | 63 | Auvinen A, Määttänen L, Finne P, Stenman UH, Aro J, Juusela H, Rannikko S, Tammela TL, Hakama M. | Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial. | Int J Cancer | 111 | 6 | 940-3 | 2004 |
| PSA | 64 | McLernon DJ, Donnan PT, Gray M, Weller D, Sullivan F. | Receiver operating characteristics of the prostate specific antigen test in an unselected population. | J Med Screen | 13 | 2 | 102-7 | 2006 |
| PSA | 65 | Postma R, van Leenders AG, Roobol MJ, Schröder FH, van der Kwast TH. | Tumour features in the control and screening arm of a randomized trial of prostate cancer. | Eur Urol | 50 | 1 | 70-5 | 2006 |
| 66 | Kubota Y, Ito K, Imai K, Yamanaka H. | Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. | Prostate | 50 | 4 | 262-9 | 2002 | |
| PSA | 67 | McGregor M, Hanley JA, Boivin JF, McLean RG. | Screening for prostate cancer: estimating the magnitude of overdetection. | CMAJ | 159 | 11 | 1368-72 | 1998 |
| PSA | 68 | Hugosson J, Aus G, Becker C, Carlsson S, Eriksson H, Lilja H, Lodding P, Tibblin G. | Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. | BJU Int | 85 | 9 | 1078-84 | 2000 |
| PSA | 69 | Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. | Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. | J Natl Cancer Inst | 94 | 13 | 981-90 | 2002 |
| PSA | 70 | Auvin A, Määttänen L, Stenman UH, Tammela T, Rannikko S, Aro J, Juusela H, Hakama M. | Lead-time in prostate cancer screening (Finland). | Cancer Causes Control | 13 | 3 | 279-85 | 2002 |
| PSA | 71 | Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ. | Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. | J Natl Cancer Inst | 95 | 12 | 868-78 | 2003 |
| PSA | 72 | Törnblom M, Eriksson H, Franzén S, Gustafsson O, Lilja H, Norming U, Hugosson J. | Lead time associated with screening for prostate cancer. | Int J Cancer | 108 | 1 | 122-9 | 2004 |
| PSA | 73 | Rietbergen JB, Kruger AE, Kranse R, Schröder FH. | Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. | Urology | 49 | 6 | 875-80 | 1997 |
| PSA | 74 | Mkinen T, Auvinen A, Hakama M, Stenman UH, Tammela TL. | Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. | Urology | 60 | 5 | 846-50 | 2002 |
| PSA | 75 | Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schönitzer D, Severi G, Robertson C, Boyle P, Bartsch G. | Screening for prostate cancer: updated experience from the Tyrol study. | Can J Urol | 12 | Suppl 1 | 7-13 | 2005 |
| 76 | Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, Graham E, Echols RM, Whalen E, Kowalsky SF. | Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. | Urology | 52 | 4 | 552-8 | 1998 | |
| 77 | Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD. | Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. 1990. | J Urol | 167 | 2 Pt 2 | 966-75 | 2002 | |
| 78 | Rodríguez LV, Terris MK. | Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. | J Urol | 160 | 6 Pt 1 | 2115-20 | 1998 | |
| 79 | Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, Borkowski A, Schulman C, Marberger M. | Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. | J Urol | 166 | 3 | 856-60 | 2001 | |
| 80 | Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. | Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. | Urology | 60 | 5 | 826-30 | 2002 | |
| 81 | Crawford ED, Haynes AL Jr, Story MW, Borden TA. | Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy. | J Urol | 127 | 3 | 449-51 | 1982 | |
| 82 | Aron M, Rajeev TP, Gupta NP. | Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. | BJU Int | 85 | 6 | 682-5 | 2000 | |
| 83 | Norberg M, Holmberg L, Häggman M, Magnusson A. | Determinants of complications after multiple transrectal core biopsies of the prostate. | Eur Radiol | 6 | 4 | 457-61 | 1996 | |
| 84 | 熊谷章，小川大輔，小山敏樹，竹内一郎，大山格． | 経直腸的前立腺生検後にフルニエ壊疽を発症した管理不良な糖尿病患者の1例． | 日本泌尿器科学会雑誌 | 93 | 5 | 648-51 | 2002 | |
| 85 | 長谷川太郎，下村達也，山田裕紀，伊藤博之，加藤伸樹，長谷川倫男，浅野晃司，清田浩，池本庸，小野寺昭一，大石幸彦． | 経直腸的前立腺針生検による敗血症性ショックの1死亡例． | 感染症学雑誌 | 76 | 10 | 893-7 | 2002 | |
| PSA | 86 | Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. | Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. | JAMA | 283 | 3 | 354-60 | 2000 |
| PSA | 87 | Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, Kupelian PA. | The use of treatments for erectile dysfunction among survivors of prostate carcinoma. | Cancer | 95 | 11 | 2397-407 | 2002 |
| PSA | 88 | Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. | An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. | JAMA | 269 | 20 | 2633-6 | 1993 |
| PSA | 89 | Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlén BJ, Holmberg L; Scandinavian Prostatic Cancer Group Study Number 4. | Quality of life after radical prostatectomy or watchful waiting. | N Engl J Med | 347 | 11 | 790-6 | 2002 |
| PSA | 90 | Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC. | Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. | J Natl Cancer Inst | 96 | 18 | 1358-67 | 2004 |
| PSA | 91 | Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC. | Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. | J Natl Cancer Inst | 92 | 19 | 1582-92 | 2000 |
| PSA | 92 | Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schröder FH. | Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. | J Clin Oncol | 19 | 6 | 1619-28 | 2001 |
| PSA | 93 | Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, Wishnow KI, Kaplan I, Loughlin KR, Richie JP, Kantoff PW. | Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. | J Clin Oncol | 16 | 1 | 275-83 | 1998 |
| 94 | Arai Y, Egawa S, Tobisu K, Sagiyama K, Sumiyoshi Y, Hashine K, Kawakita M, Matsuda T, Matsumoto K, Fujimoto H, Okada T, Kakehi Y, Terachi T, Ogawa O. | Radical retropubic prostatectomy: time trends, morbidity and mortality in Japan. | BJU Int. | 85 | 3 | 287-94 | 2000 | |
| 95 | Hisasue S, Takahashi A, Kato R, Shimizu T, Masumori N, Itoh N, Tsukamoto T. | Early and late complications of radical retropubic prostatectomy: experience in a single institution. | Jpn J Clin Oncol | 34 | 5 | 274-9 | 2004 |
